We are live on ! Find out more
OMED

OncoMed Pharmaceuticals, Inc.
OMED

Delisted

OMED was delisted on the 22nd of April, 2019.

83 hedge funds and large institutions have $247M invested in OncoMed Pharmaceuticals, Inc. in 2015 Q4 according to their latest regulatory filings, with 8 funds opening new positions, 37 increasing their positions, 20 reducing their positions, and 12 closing their positions.

New
Increased
Maintained
Reduced
Closed

200% more funds holding in top 10

Funds holding in top 10: 13 (+2)

85% more repeat investments, than reductions

Existing positions increased: 37 | Existing positions reduced: 20

48% more call options, than puts

Call options by funds: $3.19M | Put options by funds: $2.16M

41% more capital invested

Capital invested by funds: $175M → $247M (+$71.9M)

5% less funds holding

Funds holding: 8783 (-4)

33% less first-time investments, than exits

New positions opened: 8 | Existing positions closed: 12

Holders
83
Holders Change
-4
Holders Change %
-4.6%
% of All Funds
2.18%
Holding in Top 10
3
Holding in Top 10 Change
+2
Holding in Top 10 Change %
+200%
% of All Funds
0.08%
New
8
Increased
37
Reduced
20
Closed
12
Calls
$3.19M
Puts
$2.16M
Net Calls
+$1.03M
Net Calls Change
+$2.3M
Name Holding Trade Value Shares
Change
Change in
Stake
PP
51
PDT Partners
New York
$376K +$342K +16,700 New
RhumbLine Advisers
52
RhumbLine Advisers
Massachusetts
$368K +$29.4K +1,435 +10%
MLICM
53
Metropolitan Life Insurance Company (MetLife)
New York
$335K +$82.7K +4,035 +37%
Goldman Sachs
54
Goldman Sachs
New York
$323K +$111K +5,440 +61%
Bank of Montreal
55
Bank of Montreal
Ontario, Canada
$316K -$61.5K -3,000 -18%
Citigroup
56
Citigroup
New York
$292K +$127K +6,218 +92%
UBS Group
57
UBS Group
Switzerland
$279K +$169K +8,272 +201%
AllianceBernstein
58
AllianceBernstein
Tennessee
$257K -$28.7K -1,400 -11%
Barclays
59
Barclays
United Kingdom
$254K +$50.3K +2,456 +27%
Swiss National Bank
60
Swiss National Bank
Switzerland
$248K
AIG
61
American International Group
New York
$226K -$369 -18 -0.2%
Simplex Trading
62
Simplex Trading
Illinois
$225K +$109K +5,336 +114%
CG
63
Cutler Group
California
$182K +$166K +8,107 New
BWA
64
Burt Wealth Advisors
Maryland
$169K
BA
65
BlackRock Advisors
Delaware
$157K -$67.7K -3,302 -32%
Citadel Advisors
66
Citadel Advisors
Florida
$127K +$116K +5,648 New
US Bancorp
67
US Bancorp
Minnesota
$115K +$1.5K +73 +1%
Group One Trading
68
Group One Trading
Illinois
$109K -$459K -22,389 -82%
BNP Paribas Financial Markets
69
BNP Paribas Financial Markets
France
$75.2K -$3.5K -171 -5%
Legal & General Group
70
Legal & General Group
United Kingdom
$53K
CLOS
71
Compagnie Lombard Odier SCmA
Switzerland
$34K
Teacher Retirement System of Texas
72
Teacher Retirement System of Texas
Texas
$22K -$6K -293 -23%
BG
73
BlackRock Group
United Kingdom
$20K
BlackRock
74
BlackRock
New York
$13K +$5.74K +280 +95%
ClearBridge Investments
75
ClearBridge Investments
New York
$9K

OMED Hedge Fund Activity: Q4 2015 in Review

83 of the 3,812 institutional investors tracked by Wall St. Rank reported a position in OncoMed Pharmaceuticals, Inc. (OMED) for Q4 2015, worth a combined $247M — up 41% from $175M a quarter earlier.

Sellers outnumbered buyers: 12 funds closed out of OMED and 8 opened new positions — a net loss of 4 holders — while 20 trimmed existing stakes and 37 added.

The largest buyer was Iguana Healthcare Management, adding an estimated $5.63M. The largest seller was BVF Inc, cutting an estimated $7.88M.

  • 83 institutional investors held OncoMed Pharmaceuticals, Inc. (OMED) as of Q4 2015, down from 87 in Q3 2015.
  • Funds reported $247M of OncoMed Pharmaceuticals, Inc. stock for Q4 2015, up 41% quarter-over-quarter.
  • 8 funds opened new OncoMed Pharmaceuticals, Inc. positions in Q4 2015 and 12 closed out, a net change of -4 holders.
  • The largest OncoMed Pharmaceuticals, Inc. buyer in Q4 2015 was Iguana Healthcare Management, an estimated $5.63M added.
  • The largest OncoMed Pharmaceuticals, Inc. seller in Q4 2015 was BVF Inc, an estimated $7.88M sold.

Based on aggregated 13F filings for Q4 2015.